Webinar Topic
EU Clinical Trials Regulation (EU) No 536/214 – Submission and Authorisation Process
Webinar Date & Time
25 August 2016 from 10:00 to 11:30 (CET)
Webinar Overview
European Legislation for Clinical Trials
EU has come forward with legislation for clinical trials in the form of a Directive in 2001 (Dir. 2001/20 EC) that had to be transposed into national law by the Member States in 2004. More than a decade has passed since then and all stakeholders gained vast experience with the European system. Although many positive elements can be recognised in the current legislation, overall, the Directive did not fulfil the expectations. Member States used their right to “add on” to the core legislation that was set out in the Directive. As a consequence, national particularities worked against harmonisation. In multi-national clinical trials, the requirement to submit in every Member State adds to the administrative burden and is perceived as duplication of work. The goal to make the EU an attractive place for clinical research seems to be jeopardised. The fact that the number of clinical trials in the EU has declined by about 25% over the last 5-8 years, might be – among other reasons - also based on the current landscape for clinical trials in the EU.
The new regulatory approach: a new EU “Regulation” on clinical trials ((EU) No 536/2014) is in force since 16 June 2014 and will repeal Directive 2001/20/EC as soon as the Regulation is coming into effect. Latest publication by the EMA states that the new Regulation will apply in October 2018.
Stakeholders will face a number of changes, be it pertaining to definitions, the scope of the Regulation or the submission and authorisation process. Other procedures like informed consent, safety reporting and labelling of IMPs are affected as well by the new Regulation. Last but not least, new rules for transparency will change the environment for clinical trials drastically.
This webinar is the 2nd of a series of webinars on the EU Clinical Trials Regulation (EU) No 536/2014. After the first webinar on definitions and scope of the Regulation, this webinar will cover the future submission and authorisation process of clinical trials in the EU. Safety procedures and informed consent procedures will be upcoming topics.
Agenda
Clinical Trial Submission and Authorisation Process
- Initial Application
- Substantial Modifications
- Subsequent Addition of a Member State Concerned
Application Dossier
Presenters
Dr. Dagmar Chase, Vice-President EUCROF
Managing Director Clinrex GmbH
Attendance Fee
€ 90,- for EUCROF non-members
€ 60,- for EUCROF members only.
Deadline for registration
24 August 2016
How to register?
1) Click on the green "REGISTER" button on Eventbrite
2) Check your order and click on the green "CHECKOUT" button
3) Fill in all necessaary informations and validate your order
Confirmation
You will receive 2 confirmations email :
A) One from Eventbrite with you invoice
B) One from "GoToWebinar", our new Webinar platform, with all necessary informaiton to connect the D-Day!
Questions?
Should you have any questions about registration, invoices or connexion, do not hesitate to contact us by email This email address is being protected from spambots. You need JavaScript enabled to view it.